Publications

Zanidatamab Zovodotin

Categories
Zanidatamab Zovodotin
September 12, 2022
ESMO
Preliminary Results From a Phase 1 Study Using the Bispecific, Human Epidermal Growth Factor 2 (HER2)-targeting Antibody-drug Conjugate (ADC) Zanidatamab Zovodotin (ZW49) in Solid Cancers
Jhaveri et al.
Zanidatamab Zovodotin
April 14, 2018 - April 18, 2018
AACR
ZW49, a HER2 targeted biparatopic antibody drug conjugate for the treatment of HER2 expressing cancers
Hamblett et al.